TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Brief Summary: The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Importance of Electrical Stimulation as a Treatment for Urinary Incontinence in Patients Undergoing Prostatectomy to Exercise the Pelvic Floor Muscles (MAPs): Randomised Controlled Trial, Double Blind
Brief Summary: The use of electrical stimulation to reduce urinary incontinence in men undergoing prostatectomy exercises of the pelvic floor muscles (MAPs)


Options:
A: Arm Label: electrostimulation with exercises MAPs; Type: EXPERIMENTAL; Interventions: Other: electrostimulation with exercises MAPs | Arm Label: exercises MAPs; Type: ACTIVE_COMPARATOR; Interventions: Other: exercises MAPs | Intervention Type: OTHER; Name: electrostimulation with exercises MAPs; Assigned to Arm(s): electrostimulation with exercises MAPs | Intervention Type: OTHER; Name: exercises MAPs; Assigned to Arm(s): exercises MAPs
B: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: biofeedback; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE) | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE) | Intervention Type: DEVICE; Name: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE); Assigned to Arm(s): Group 1, Group 2
D: Arm Label: BF+SUPPORT; Type: EXPERIMENTAL; Interventions: Behavioral: BF+SUPPORT | Arm Label: BF+PHONE; Type: EXPERIMENTAL; Interventions: Behavioral: BF+PHONE | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BF+SUPPORT; Assigned to Arm(s): BF+SUPPORT | Intervention Type: BEHAVIORAL; Name: BF+PHONE; Assigned to Arm(s): BF+PHONE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial
Brief Summary: The investigators hypothesize that preoperative administration of 8 mg IV dexamethasone will benefit patients' perceived quality of recovery after surgery.


Options:
A: Arm Label: Ultrasound guided bilateral TAP block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus abdominis plane block (TAP BLOCK) | Arm Label: Instillation of surgical site with local anesthestic.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Instillation of surgical site with local anesthetic. | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Opioid IV medications (Control) | Intervention Type: PROCEDURE; Name: Transversus abdominis plane block (TAP BLOCK); Assigned to Arm(s): Ultrasound guided bilateral TAP block | Intervention Type: PROCEDURE; Name: Instillation of surgical site with local anesthetic.; Assigned to Arm(s): Instillation of surgical site with local anesthestic. | Intervention Type: PROCEDURE; Name: Opioid IV medications (Control); Assigned to Arm(s): Control Group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic NaCl | Arm Label: dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone phosphate | Intervention Type: DRUG; Name: dexamethasone phosphate; Assigned to Arm(s): dexamethasone | Intervention Type: DRUG; Name: Isotonic NaCl; Assigned to Arm(s): Placebo
C: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial
Brief Summary: The investigators hypothesize that preoperative administration of 8 mg IV dexamethasone will benefit patients' perceived quality of recovery after surgery.


Options:
A: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT
C: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mechanical Bowel Prep; Type: ACTIVE_COMPARATOR; Interventions: Other: Mechanical Bowel Prep | Arm Label: No Mechanical Bowel Prep.; Type: ACTIVE_COMPARATOR; Interventions: Other: No Mechanical Bowel Prep | Intervention Type: OTHER; Name: Mechanical Bowel Prep; Assigned to Arm(s): Mechanical Bowel Prep | Intervention Type: OTHER; Name: No Mechanical Bowel Prep; Assigned to Arm(s): No Mechanical Bowel Prep.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to assess the efficacy of Gabapentin (Carbatin \& Neurontin) in patients with neuropathy pain.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: OTHER; Interventions: Drug: Pregabalin | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
D: Arm Label: Carbatin; Type: EXPERIMENTAL; Interventions: Drug: Carbatin | Arm Label: Neurontin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neurontin | Intervention Type: DRUG; Name: Carbatin; Assigned to Arm(s): Carbatin | Intervention Type: DRUG; Name: Neurontin; Assigned to Arm(s): Neurontin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Application of Appropriate Technology for Obesity Prevention and Control -- Study on Personalized Aerobic and Appropriate Exercise Technology
Brief Summary: The primary objective of this study is to assess the effectiveness of a school based physical activity programme on obesity and related health outcomes in young schoolchildren.


Options:
A: Arm Label: Daily physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Daily physical activity intervention | Arm Label: Control - treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily physical activity intervention; Assigned to Arm(s): Daily physical activity intervention
B: Arm Label: School-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Trial of Activity for Adolescent Girls (TAAG) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trial of Activity for Adolescent Girls (TAAG); Assigned to Arm(s): School-based intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity guidance, Behavioral: Health education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity guidance; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Short Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short-term educational program | Arm Label: Long Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long-term educational program | Intervention Type: BEHAVIORAL; Name: Long-term educational program; Assigned to Arm(s): Long Intervention | Intervention Type: BEHAVIORAL; Name: Short-term educational program; Assigned to Arm(s): Short Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Application of Appropriate Technology for Obesity Prevention and Control -- Study on Personalized Aerobic and Appropriate Exercise Technology
Brief Summary: The primary objective of this study is to assess the effectiveness of a school based physical activity programme on obesity and related health outcomes in young schoolchildren.


Options:
A: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity guidance, Behavioral: Health education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity guidance; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Intervention
D: Arm Label: LA Sprouts intervention; Type: EXPERIMENTAL; Interventions: Behavioral: LA Sprouts intervention | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: LA Sprouts intervention; Assigned to Arm(s): LA Sprouts intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the IntellO2 - Precision Flow Automatic FiO2 Controller to Manual Control for Optimizing Oxygenation in Preterm Infants Receiving High Flow Nasal Cannula Therapy
Brief Summary: The overall objective of this study is to demonstrate that the IntellO2 device providing automated control of fraction of inspired oxygen (FiO2) adjustments in spontaneously breathing infants with fluctuating arterial blood oxygen saturation levels is safe and efficacious in the routine clinical environment. Specifically, it is hypothesized that the IntellO2 will perform as well or better than standard practice for maintaining infants' arterial blood oxygen saturation in a target range while minimizing the exposure to elevated levels of oxygen in the inspired gas.


Options:
A: Arm Label: RMC only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CLAC slow; Type: ACTIVE_COMPARATOR; Interventions: Device: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC | Arm Label: CLAC fast; Type: EXPERIMENTAL; Interventions: Device: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC | Intervention Type: DEVICE; Name: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC; Assigned to Arm(s): CLAC fast | Intervention Type: DEVICE; Name: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC; Assigned to Arm(s): CLAC slow
B: Arm Label: IntellO2; Type: EXPERIMENTAL; Interventions: Device: IntellO2 | Arm Label: Manual; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual control | Intervention Type: DEVICE; Name: IntellO2; Assigned to Arm(s): IntellO2 | Intervention Type: OTHER; Name: Manual control; Assigned to Arm(s): Manual
C: Arm Label: Automated FiO2 control; Type: EXPERIMENTAL; Interventions: Device: Automated FiO2 Control | Arm Label: Manual Adjustment; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: Automated FiO2 Control; Assigned to Arm(s): Automated FiO2 control
D: Arm Label: Experimental: device FreeO.; Type: EXPERIMENTAL; Interventions: Device: FreeO2 v2.0 automatic adjustment | Arm Label: Manual oxygenation; Type: ACTIVE_COMPARATOR; Interventions: Device: FreeO2 v2.0 data collecting | Intervention Type: DEVICE; Name: FreeO2 v2.0 automatic adjustment; Assigned to Arm(s): Experimental: device FreeO. | Intervention Type: DEVICE; Name: FreeO2 v2.0 data collecting; Assigned to Arm(s): Manual oxygenation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Inspiratory Muscle Training (IMT) on Dyspnea in COPD During Pulmonary Rehabilitation: Randomized Controlled Trial
Brief Summary: Demonstrate that IMT associated with a conventional pulmonary rehabilitation program allows a significant improvement of dyspnea in subjects with severe or very severe COPD than a conventional pulmonary rehabilitation program alone.


Options:
A: Intervention Type: OTHER; Name: inspiratory muscle training; Assigned to Arm(s): N/A
B: Arm Label: Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: inspiratory pressure training group; Type: EXPERIMENTAL; Interventions: Device: inspiratory pressure training group | Arm Label: mixed training group; Type: EXPERIMENTAL; Interventions: Device: mixed training group | Intervention Type: DEVICE; Name: inspiratory pressure training group; Assigned to Arm(s): inspiratory pressure training group | Intervention Type: DEVICE; Name: mixed training group; Assigned to Arm(s): mixed training group
D: Arm Label: Test of Incremental Respiratory Endurance - IMT; Type: EXPERIMENTAL; Interventions: Device: Test of Incremental Respiratory Endurance - IMT | Arm Label: Threshold - IMT; Type: EXPERIMENTAL; Interventions: Device: Threshold - IMT | Arm Label: Sham IMT (Low resistence); Type: SHAM_COMPARATOR; Interventions: Device: Sham IMT (Low resistence) | Intervention Type: DEVICE; Name: Test of Incremental Respiratory Endurance - IMT; Assigned to Arm(s): Test of Incremental Respiratory Endurance - IMT | Intervention Type: DEVICE; Name: Threshold - IMT; Assigned to Arm(s): Threshold - IMT | Intervention Type: DEVICE; Name: Sham IMT (Low resistence); Assigned to Arm(s): Sham IMT (Low resistence)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
Brief Summary: This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis


Options:
A: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
C: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg
D: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab

Answer: D